Epileptic Seizures Treatment Market, by Drug Type (First Generation, Second Generation, and Third Generation), by Seizure Type (Partial Seizures, Generalized Seizures, and Unclassified Seizures), by Route of Administration (Oral/Buccal, Nasal, Rectal, and

Epileptic Seizures Treatment Market, by Drug Type (First Generation, Second Generation, and Third Generation), by Seizure Type (Partial Seizures, Generalized Seizures, and Unclassified Seizures), by Route of Administration (Oral/Buccal, Nasal, Rectal, and Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Epilepsy is a chronic disorder that causes unprovoked and recurrent seizures. A seizure is a sudden rush of electrical activity in the brain. Epilepsy is associated with disrupted activities in the brain called seizures, which affects the central nervous system. Epilepsy is categorized into generalized seizures and partial seizures based on the areas affected in the brain. An increasing number of epilepsy cases is expected to drive growth of the global epileptic seizures treatment market. For instance, according to the study by Epilepsy Action Australia statistics in 2017, around 50 million people globally had epilepsy with around 80% of the people living in emerging economies such as India, Brazil, and China.
Moreover, increasing launches of drugs for treatment of epilepsy is expected to create conducive environment for the market growth. For instance, in 2016, UCB Pharma Limited received the U.S. FDA approval for Briviact, for the treatment of patients with partial onset of seizures. Moreover, Mylan launched generic, Felbatol tablets for the treatment of epileptic seizures, in the U.S. after receiving approval from the U.S. Food & Drug Administration in 2016. These factors are expected to boost the market growth over the forecast period.
Market Dynamics
The increasing prevalence of epilepsy in adults and children, across the globe is expected to drive growth of the epileptic seizures treatment market during the forecast period. According to the WHO, around one-third of children with epilepsy can be assigned to a specific epilepsy syndrome, as defined by the most recently proposed system for organization of epilepsy syndrome. According to the Society of Neuroscience, in 2015, epilepsy affected around 10.5 million children worldwide, and the types and severity of the disorder varied significantly. Moreover, according to the American Academy of Pediatrics data published in April 2017, epilepsy affects 0.5% to 1% of children globally, and is the most frequently occurring chronic neurologic condition in childhood.
However, non‐conventional anti-epileptic treatments and non‐pharmacological approaches can potentially help in reduction of seizures or anti-epileptic drug toxicity. For instance, there has been increasing preference for alternative therapy for epilepsy such as corticosteroids, immunoglobulins, melatonin, and vitamins for treating children. Other than supplemental therapy, there are certain techniques that can help reduce epileptic seizures such as avoidance technique, which involves avoiding activities that can induce a seizure such as flickering lights, listening to specific type or piece of music, eating, reading, and immersion in hot water, chess playing, or brushing hair. Thus, these factors are expected to restrain the epileptic seizures treatment market growth. Other non‐pharmacological treatments for epilepsy in children include herbal medicine, homeopathy, yoga, aromatherapy, and coping strategies.
Key features of the study:
This report provides in-depth analysis of the global epileptic seizures treatment market, market size (US$ Bn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global epileptic seizures treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Sanofi S.A., Mylan N.V., Bausch Health Companies Inc., UCB S.A., Eisai Co. Ltd., Abbott Laboratories, Sumitomo Dainippon Pharma Co., Ltd., GW Pharmaceuticals Plc, Marinus Pharmaceuticals, Inc., H. Lundbeck A/S, and Takeda Pharmaceutical Co., Ltd.
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global epileptic seizures treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for epileptic seizures treatment market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:
Global Epileptic Seizures Treatment Market, By Drug Type:
First Generation
Second Generation
Third Generation
Global Epileptic Seizures Treatment Market, By Seizure Type:
Partial Seizures
Generalized Seizures
Unclassified Seizures
Global Epileptic Seizures Treatment Market, By Route of Administration:
Oral/Buccal
Nasal
Rectal
Parenteral
Global Epileptic Seizures Treatment Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Epileptic Seizures Treatment Market, By Region:
North America
By Country:
U.S.
Canada
By Drug Type:
First Generation
Second Generation
Third Generation
By Seizure Type:
Partial Seizures
Generalized Seizures
Unclassified Seizures
By Route of Administration:
Oral/Buccal
Nasal
Rectal
Parenteral
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Type:
First Generation
Second Generation
Third Generation
By Seizure Type:
Partial Seizures
Generalized Seizures
Unclassified Seizures
By Route of Administration:
Oral/Buccal
Nasal
Rectal
Parenteral
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Type:
First Generation
Second Generation
Third Generation
By Seizure Type:
Partial Seizures
Generalized Seizures
Unclassified Seizures
By Route of Administration:
Oral/Buccal
Nasal
Rectal
Parenteral
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Type:
First Generation
Second Generation
Third Generation
By Seizure Type:
Partial Seizures
Generalized Seizures
Unclassified Seizures
By Route of Administration:
Oral/Buccal
Nasal
Rectal
Parenteral
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drug Type:
First Generation
Second Generation
Third Generation
By Seizure Type:
Partial Seizures
Generalized Seizures
Unclassified Seizures
By Route of Administration:
Oral/Buccal
Nasal
Rectal
Parenteral
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Drug Type:
First Generation
Second Generation
Third Generation
By Seizure Type:
Partial Seizures
Generalized Seizures
Unclassified Seizures
By Route of Administration:
Oral/Buccal
Nasal
Rectal
Parenteral
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Novartis AG *
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
GlaxoSmithKline Plc
Johnson & Johnson Service, Inc.
Teva Pharmaceutical Industries Ltd.
Pfizer, Inc.
Sanofi S.A.
Mylan N.V.
Bausch Health Companies Inc.
UCB S.A
Eisai Co. Ltd.
Abbott Laboratories
Sumitomo Dainippon Pharma Co., Ltd.
GW Pharmaceuticals Plc
Marinus Pharmaceuticals, Inc.
H. Lundbeck A/S
Takeda Pharmaceutical Co., Ltd.
“*” marked represents similar segmentation in other categories in the respective section.